The destination is to get to a point where we can spend our healthcare resources more wisely so that patients get the care they need and we all get the type of innovation that we really want, said Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
The destination is to get to a point where we can spend our healthcare resources more wisely so that patients get the care they need and we all get the type of innovation that we really want, said Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
Trascript (slightly modified)
What do you think are the most important questions that currently need to be addressed in the conversation about healthcare spending?
I think there’s a number of important questions that need to be addressed regarding healthcare spending, and I think there’s tier 1 questions and tier 2 questions. The tier 1 questions are really the high-level ones: How much do we want to spend on healthcare in the United States? And then, how do we allocate those dollars? So those are the high-level questions.
Then underneath it is where it gets to be difficult. It’s what I like to call the third rail questions: should we be spending more in preventive care than actual treatment? Should we be spending different amounts on end-of-life care or on the elderly versus the younger folks? Should we be spending the same amount on cancer care that we do today, or should we allocate those resources differently? That’s the second-tier questions, and those frankly are the really tough ones, but unless we address those, we really won’t come up with any solutions.
What will the consequences be for the US economy if unchecked healthcare spending is not addressed?
Too often we say the problem is drug spending or the problem is hospital consolidation raising the cost of going into the hospital. That’s looking at things individually and finger pointing. What we need to do is not just look at the costs of these services, but also the benefits. So, what’s the cost of hospital care, and what are the benefits? What are the costs of medications or devices or surgery, and what are the benefits?
Only by looking at those side by side can we decide, “You know, I think we’d be better off reallocating some of our resources, which are currently being spent on things that are not high value, and shifting those dollars towards things that in fact are high value.”
We are on a journey, and the journey really is to begin to talk about these kind of things, but the destination isn’t just to talk. The destination is to get to a point where we can spend our healthcare resources more wisely so that patients get the care they need and we all get the type of innovation that we really want.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More